Evanthia Galanis, MD

Mayo Clinic, Chair, Department of Molecular Medicine

What is your current professional status?

Professor of Oncology and Sandra J. Schulze Professor of Novel Therapeutics; Chair, Department of Molecular Medicine, Mayo Clinic; Leader of the Virus and Gene Therapy Program of the MCCC

What is your work setting?

Academic institution

What is your scientific area of research?

Novel virotherapy and immunovirotherapy approaches in the treatment of cancer.

Why do you want to be a mentor?

It is always a pleasure to interact with and learn from motivated young investigators.

As a mentor, what are you hoping to gain from this experience?

The satisfaction of fostering the career development of the next generation of scientists and translational researchers.

How important are the following in the selection of a mentee?
(1 – 5 scale, 1 = most important, 5 = least important)

  • Compatibility of Scientific Specialties: 1 (most)
  • Geographic Location: 5 (least)
  • Professional Status / Success: 5 (least)
  • Compatibility of Career Path: 2
  • Communication Style: 3

Summarize in a brief paragraph (150 words or less), please provide a biography that describes who you are and what you do in the field of gene and/or cell therapy:

My research focuses on the development and optimization of novel virotherapy and immunovirotherapy approaches in the treatment of cancer. The focus of my laboratory is to develop and optimize novel virotherapy approaches in the treatment of cancer with special emphasis on paramyxoviruses. We have pioneered a number of innovative approaches including trackable markers; combinations with small molecules, cytotoxic agents and radiation therapy; retargeting of viral strains against tumor specific antigens and tumor stem cells; novel viral delivery approaches such as cell mediated delivery into tumor targets; and immunomodulatory strategies to modify humoral and innate immunity as a means of further increasing viral replication in vivo.

A significant impetus for my research has been the translation of laboratory advances into clinical trials of novel virotherapeutics in cancer patients: I have spearheaded the bench to bedside translation of measles derivatives and their first in human testing in clinical trials for cancer patients, including testing of engineered measles virus strains in platinum refractory ovarian cancer and recurrent glioblastoma patients as well as first in human testing of virus infected mesenchymal stem cells as a novel anticancer therapy. I have also served as the principal investigator in multiple phase I/II virotherapy trials in solid tumors testing different DNA and RNA viral platforms.

22nd Annual Meeting
April 29 – May 2 | Washington D.C.